Ryvu Therapeutics Ratios and Metrics

Market cap in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	347	627	1,780	1,329	903	1,120
Market Cap Growth	-51.46%	-64.80%	33.91%	47.23%	-19.35%	23.98%
Enterprise Value	359.73	590.6	1,621	1,078	560.34	1,037
Last Close Price	15.00	27.10	38.50	57.50	49.25	61.00
Forward PE	-	163.70	163.70	163.70	163.70	163.70
PEG Ratio	-	0.70	0.70	0.70	0.70	0.70
PS Ratio	3.92	7.14	17.45	19.55	12.81	30.99
PB Ratio	8.39	11.64	11.69	143.75	2.63	6.94
P/TBV Ratio	9.90	13.11	6.17	142.37	2.65	7.08
P/FCF Ratio	-	-	-	-	45.60	-
P/OCF Ratio	-	-	-	-	42.36	-
EV/Sales Ratio	4.07	6.73	15.89	15.86	7.95	28.69
EV/FCF Ratio	-	-	-	-	28.30	-
Debt / Equity Ratio	1.77	1.33	0.44	0	0.01	0.02
Debt / FCF Ratio	-	-	-	-	0.14	-
Net Debt / Equity Ratio	-0.23	-0.67	-1.04	-27.16	-1.00	-0.52
Net Debt / EBITDA Ratio	0.13	0.37	1.42	2.79	5.23	1.26
Net Debt / FCF Ratio	0.09	0.30	1.17	2.70	-17.30	1.17
Asset Turnover	0.42	0.29	0.26	0.15	0.20	0.14
Quick Ratio	2.04	2.07	2.42	4.07	8.09	2.76
Current Ratio	2.26	2.26	2.52	4.07	8.21	2.88
Return on Equity (ROE)	-172.50%	-98.22%	-54.11%	-30.55%	-33.20%	-41.08%
Return on Assets (ROA)	-38.59%	-35.71%	-31.31%	-22.99%	-23.58%	-30.02%
Return on Invested Capital (ROIC)	-330.03%	-1898.83%	-12832.84%	-2196.67%	-210.32%	-106.31%
Return on Capital Employed (ROCE)	-52.60%	-49.62%	-40.41%	-26.44%	-25.18%	-34.59%
FCF Yield	-	-	-	-	2.19%	-
Buyback Yield / Dilution	4.90%	0.00%	-0.97%	-24.75%	0.00%	-9.48%
Total Shareholder Return	4.90%	0.00%	-0.97%	-24.75%	0.00%	-9.48%